From Nobel-cited discoveries to first-in-class drug mechanisms, our scientists push the boundaries of what medicine can achieve.
Veridian researchers demonstrated a modular mRNA vaccine framework capable of rapid adaptation to novel coronavirus variants. The platform achieved >92% neutralisation against all tested SARS-CoV-2 variants and Beta-coronavirus strains in a Phase II trial of 4,200 participants, establishing a new paradigm for pandemic preparedness.
The molecular basis for Veritacel-X7™'s efficacy was elucidated: beyond direct KRAS inhibition, the compound restores MHC-I expression on tumour cells, enabling cytotoxic T-cell recognition. This dual mechanism explains the 58% ORR observed in NSCLC and has opened a new combination approach with PD-1 checkpoint inhibitors.
CardioShield-HF™ was shown to directly reduce myocardial fibrosis in HFrEF patients independent of its glucose-lowering effects. Cardiac MRI substudy of 1,800 patients revealed a 31% reduction in extracellular volume fraction after 52 weeks, explaining the drug's mortality benefit beyond metabolic mechanisms.
VRD-NP2 (NeuroPath-PD™ pipeline compound) was demonstrated to intercept early-stage alpha-synuclein aggregation by stabilising a non-pathogenic conformation. Drosophila and NHP models showed 78% preservation of dopaminergic neurons. This publication triggered accelerated Phase II designation from the FDA.
A previously unknown mechanism of Veritacel-IMM™ was uncovered: in addition to PD-L1 checkpoint blockade, velotumab normalises tumour vasculature, improving perfusion and enabling superior co-drug penetration. This finding spawned two new combination trials now enrolling in Phase III.
| Compound | Therapeutic Area | Indication | Mechanism | Phase | Est. Milestone |
|---|---|---|---|---|---|
| Veritacel-X7™ | Oncology | NSCLC · CRC | KRASG12C inhibitor | Approved | Label expansion 2026 |
| Veritacel-IMM™ | Oncology | TNBC · Bladder Ca. | Anti-PD-L1 mAb | Approved | New combination 2027 |
| Veritacel-ADC™ | Oncology | Gastric · Breast Ca. | HER2-targeted ADC | Phase III | Filing Q3 2027 |
| VRD-ONC-04 | Oncology | Ovarian Ca. | PARP inhibitor + WEE1 | Phase II | Phase III 2026 |
| CardioShield-HF™ | Cardiology | HFrEF · T2DM | SGLT2 inhibitor | Approved | HFpEF trial 2026 |
| VRD-CV-02 | Cardiology | Atherosclerosis | PCSK9 siRNA | Phase III | Filing Q1 2027 |
| NeuroPath-MS™ | Neurology | RRMS · SPMS | S1P receptor modulator | Approved | SPMS extension 2026 |
| NeuroPath-PD™ | Neurology | Parkinson's disease | Alpha-syn chaperone | Phase II | Phase III 2027 |
| VRD-NR-03 | Neurology | Alzheimer's disease | Tau aggregation inhibitor | Phase I | Phase II 2027 |
| Vericel-AV™ | Infectious Disease | Influenza · RSV | RNA polymerase inhibitor | Approved | Paediatric label 2026 |
| VRD-ID-02 | Infectious Disease | MDR Tuberculosis | Novel DprE1 inhibitor | Phase II | Phase III 2027 |
| OrphaVerd-1™ | Rare Disease | Pompe disease | Enzyme replacement | Approved | Next-gen ERT 2027 |
| VRD-RD-02 | Rare Disease | Spinal Muscular Atrophy | SMN2 splicing modifier | Phase III | Filing Q4 2026 |
| VaxShield-RSV™ | Vaccines | RSV (Adults 60+) | mRNA · LNP platform | Approved | Paediatric trial 2026 |
| VRD-VAX-02 | Vaccines | Influenza (Universal) | Haemagglutinin stem mRNA | Phase II | Phase III 2027 |
Phase III, randomised, double-blind study evaluating the combination of KRASG12C inhibition and PD-L1 blockade in previously treated KRAS-mutated NSCLC.
Phase II proof-of-concept study in drug-naïve patients with early-stage Parkinson's disease. Primary endpoint: DaTscan neuroimaging at 24 months.
Phase III event-driven trial examining CV outcomes with verication in HFpEF, a population with no approved disease-modifying therapy.
Awarded for Veritacel-X7™ for its first-in-class KRAS targeting mechanism.
VRD-NP2 named one of the year's top breakthroughs in neurodegeneration research.
Three pipeline compounds received BTD in one calendar year — a company record.
CardioShield-3™ added to WHO Essential Medicines List following access commitments.
Awarded to Veridian's Cardiology team for the SHIELD-HF landmark trial results.
Recognised for our AI-driven drug discovery platform and rare disease commitments.